Li Liangping

Biography

Li Liangping studied medicine at Hengyang Medical School, Hunan Province (1977-1982) and tumor biology at Cancer Institute, Sun Yat-sen University of Medicine (1985-1988) and tumor immunology at the Blankenstein group (Molecular Immunology and Gene Therapy) of MDC / Universitätsklinikum Medizinische Fakultät Charité, Der Humboldt-Universität zu Berlin, Germany (1994-1999). Under the supervision of Thomas Blankenstein he carried out studies of “Establishment of conditional immortalization system for human cells with retroviral vector of LoxP-flanked SV40 large T antigen and Cre recombinase and immortalization of primary culture of human normal mammary epithelial cells and carcinoma” for his thesis of doctoral degree. During 2000-2010, at the Molecular Immunology and Gene therapy, Max Delbruck Center for Molecular Medicine， Dr. Li and colleagues successfully transfer huge human T cell receptor loci (800-1100 kb) to mice genome and to generate and analyze T cell receptor loci transgenic mice and the results were published at Nature Medicine (2010) and Nature Protocol (2013). 2011-now: back to SYSU and established own research group and set up transgenic center for SYSU. In 2013 he successfully organized TT2013 international transgenic workshop.

Research Interest

Cancer immunology and genetically modified animal Model. Focus on the generation of genetically modified animal Model with new technology such as dRMCE and TALEN, CRISPR/CAS9